HRP20150873T1 - Pripravci i postupci za lijeäśenje celijakije - Google Patents
Pripravci i postupci za lijeäśenje celijakije Download PDFInfo
- Publication number
- HRP20150873T1 HRP20150873T1 HRP20150873TT HRP20150873T HRP20150873T1 HR P20150873 T1 HRP20150873 T1 HR P20150873T1 HR P20150873T T HRP20150873T T HR P20150873TT HR P20150873 T HRP20150873 T HR P20150873T HR P20150873 T1 HRP20150873 T1 HR P20150873T1
- Authority
- HR
- Croatia
- Prior art keywords
- peptide
- derived
- gluten
- amino acid
- biologically active
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims 21
- 208000015943 Coeliac disease Diseases 0.000 title claims 7
- 239000000203 mixture Substances 0.000 title claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 55
- 108010068370 Glutens Proteins 0.000 claims 24
- 235000021312 gluten Nutrition 0.000 claims 24
- 230000005867 T cell response Effects 0.000 claims 18
- 150000001413 amino acids Chemical class 0.000 claims 18
- 239000012634 fragment Substances 0.000 claims 12
- 125000003275 alpha amino acid group Chemical group 0.000 claims 11
- 102000004196 processed proteins & peptides Human genes 0.000 claims 11
- 229960005486 vaccine Drugs 0.000 claims 9
- 210000004027 cell Anatomy 0.000 claims 7
- 102000040430 polynucleotide Human genes 0.000 claims 7
- 108091033319 polynucleotide Proteins 0.000 claims 7
- 239000002157 polynucleotide Substances 0.000 claims 7
- 239000000427 antigen Substances 0.000 claims 5
- 102000036639 antigens Human genes 0.000 claims 5
- 108091007433 antigens Proteins 0.000 claims 5
- 210000001744 T-lymphocyte Anatomy 0.000 claims 3
- 210000000612 antigen-presenting cell Anatomy 0.000 claims 3
- 230000028327 secretion Effects 0.000 claims 3
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical group OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 claims 2
- 102000003814 Interleukin-10 Human genes 0.000 claims 2
- 108090000174 Interleukin-10 Proteins 0.000 claims 2
- 102000000588 Interleukin-2 Human genes 0.000 claims 2
- 108010002350 Interleukin-2 Proteins 0.000 claims 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 2
- 125000003368 amide group Chemical group 0.000 claims 2
- 239000012752 auxiliary agent Substances 0.000 claims 2
- 210000004899 c-terminal region Anatomy 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 235000013305 food Nutrition 0.000 claims 2
- 238000000338 in vitro Methods 0.000 claims 2
- 229940076144 interleukin-10 Drugs 0.000 claims 2
- 102000004127 Cytokines Human genes 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- 102000008070 Interferon-gamma Human genes 0.000 claims 1
- 108010074328 Interferon-gamma Proteins 0.000 claims 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 210000003719 b-lymphocyte Anatomy 0.000 claims 1
- 210000004443 dendritic cell Anatomy 0.000 claims 1
- 238000003745 diagnosis Methods 0.000 claims 1
- 210000002889 endothelial cell Anatomy 0.000 claims 1
- 230000006058 immune tolerance Effects 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 229960003130 interferon gamma Drugs 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 210000002540 macrophage Anatomy 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000012544 monitoring process Methods 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 230000004044 response Effects 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
- A61K39/4621—Cellular immunotherapy characterized by the effect or the function of the cells immunosuppressive or immunotolerising
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4632—T-cell receptors [TCR]; antibody T-cell receptor constructs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/46433—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/24—Immunology or allergic disorders
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Biotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Mycology (AREA)
- Urology & Nephrology (AREA)
- Botany (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Diabetes (AREA)
Claims (19)
1. Pripravak naznačen time da sadrži
i) prvi peptid koji sadrži sekvencu aminokiseline LQPFPQPELPYPQPQ (SEQ ID BR.: 13), njegov biološki aktivni fragment s najmanje 7 aminokiselina u duljinu i koji je sposoban generirati jednak ili veći odgovor T stanica kod subjekta osjetljivog na gluten kao peptid iz kojeg je dobiven, ili njegovu biološki aktivnu varijantu s najmanje 3 varijacije aminokiselina u odnosu na peptid iz kojeg je dobiven i koji je sposoban generirati jednak ili veći odgovor T stanica kod subjekta osjetljivog na gluten kao peptid iz kojeg je dobiven,
ii) drugi peptid koji sadrži sekvencu aminokiseline QPFPQPEQPFPWQP (SEQ ID BR.: 14), njegov biološki aktivni fragment s najmanje 7 aminokiselina u duljinu i koji je sposoban generirati jednak ili veći odgovor T stanica kod subjekta osjetljivog na gluten kao peptid iz kojeg je dobiven, ili njegovu biološki aktivnu varijantu s najmanje 3 varijacije aminokiselina u odnosu na peptid iz kojeg je dobiven i koji je sposoban generirati jednak ili veći odgovor T stanica kod subjekta osjetljivog na gluten kao peptid iz kojeg je dobiven, i
iii) treći peptid koji sadrži sekvencu aminokiseline PEQPIPEQPQPYPQQ (SEQ ID BR.: 16), njegov biološki aktivni fragment s najmanje 7 aminokiselina u duljinu i koji je sposoban generirati jednak ili veći odgovor T stanica kod subjekta osjetljivog na gluten kao peptid iz kojeg je dobiven, ili njegovu biološki aktivnu varijantu s najmanje 3 varijacije aminokiselina u odnosu na peptid iz kojeg je dobiven i koji je sposoban generirati jednak ili veći odgovor T stanica kod subjekta osjetljivog na gluten kao peptid iz kojeg je dobiven.
2. Pripravak prema zahtjevu 1, naznačen time da
(a) drugi peptid koji sadrži sekvencu aminokiseline PQQPFPQPEQPFPWQP (SEQ ID BR.: 320), njegov biološki aktivni fragment s najmanje 7 aminokiselina u duljinu i koji je sposoban generirati jednak ili veći odgovor T stanica kod subjekta osjetljivog na gluten kao peptid iz kojeg je dobiven, ili njegovu biološki aktivnu varijantu s najmanje 3 varijacije aminokiselina u odnosu na peptid iz kojeg je dobiven i koji je sposoban generirati jednak ili veći odgovor T stanica kod subjekta osjetljivog na gluten kao peptid iz kojeg je dobiven, i/ili treći peptid koji sadrži sekvencu aminokiseline FPEQPIPEQPQPYPQQ (SEQ ID BR.: 321), njegov biološki aktivni fragment s najmanje 7 aminokiselina u duljinu i koji je sposoban generirati jednak ili veći odgovor T stanica kod subjekta osjetljivog na gluten kao peptid iz kojeg je dobiven, ili njegovu biološki aktivnu varijantu s najmanje 3 varijacije aminokiselina u odnosu na peptid iz kojeg je dobiven i koji je sposoban generirati jednak ili veći odgovor T stanica kod subjekta osjetljivog na gluten kao peptid iz kojeg je dobiven;
(b) prvi, drugi i/ili treći peptidi sadrže N terminalnu acetil skupinu ili piroglutamatnu skupinu, i/ili C terminalnu amidnu skupinu, poželjno N terminalnu piroglutamatnu skupinu i C terminalnu amidnu skupinu;
(c) prvi, drugi i/ili treći peptidi su konjugirani na spoj, pri čemu spoj je poželjno pomoćno sredstvo, ili MHC molekula ili njegov vezni fragment;
(d) dva ili tri od prvog, drugog i/ili trećeg peptida, njegove biološki aktivne fragmente s ne manje od 7 aminokiselina u duljinu i koji je sposoban generirati jednak ili veći odgovor T stanica kod subjekta osjetljivog na gluten kao peptid iz kojeg je dobiven, ili njegove biološki aktivne varijante s ne više od 3 varijacije aminokiselina u odnosu na peptid iz kojeg je dobiven i koji je sposoban generirati jednak ili veći odgovor T stanica kod subjekta osjetljivog na gluten kao peptid iz kojeg je dobiven, su na jednom polipeptidnom lancu; i/ili;
(e) navedeni pripravak sadrži jedan ili više dodatnih peptida koji sadrže sekvencu aminokiseline odabranu iz skupine koja sadrži SEQ ID BR.: 47, 48, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 75, 76, 77, 78, 79, 80, 81, 89, 90, 91, 92, 95, 102, 103, 104, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 136, 169, 170, 171, 172, 173, 174, 177, 178, 179, 180, 183, 184, 187, 188, 189, 190, 191, 192, 209, i 210.
3. Pripravak naznačen time da sadrži jedan ili više polinukleotida koji kodiraju
i) prvi peptid koji sadrži sekvencu aminokiseline LQPFPQPELPYPQPQ (SEQ ID BR.: 13), njegov biološki aktivni fragment s najmanje 7 aminokiselina u duljinu i koji je sposoban generirati jednak ili veći odgovor T stanica kod subjekta osjetljivog na gluten kao peptid iz kojeg je dobiven, ili njegovu biološki aktivnu varijantu s najmanje 3 varijacije aminokiselina u odnosu na peptid iz kojeg je dobiven i koji je sposoban generirati jednak ili veći odgovor T stanica kod subjekta osjetljivog na gluten kao peptid iz kojeg je dobiven,
ii) drugi peptid koji sadrži sekvencu aminokiseline QPFPQPEQPFPWQP (SEQ ID BR.: 14), njegov biološki aktivni fragment s najmanje 7 aminokiselina u duljinu i koji je sposoban generirati jednak ili veći odgovor T stanica kod subjekta osjetljivog na gluten kao peptid iz kojeg je dobiven, ili njegovu biološki aktivnu varijantu s najmanje 3 varijacije aminokiselina u odnosu na peptid iz kojeg je dobiven i koji je sposoban generirati jednak ili veći odgovor T stanica kod subjekta osjetljivog na gluten kao peptid iz kojeg je dobiven, i
iii) treći peptid koji sadrži sekvencu aminokiseline PEQPIPEQPQPYPQQ (SEQ ID BR.: 16), njegov biološki aktivni fragment s najmanje 7 aminokiselina u duljinu i koji je sposoban generirati jednak ili veći odgovor T stanica kod subjekta osjetljivog na gluten kao peptid iz kojeg je dobiven, ili njegovu biološki aktivnu varijantu s najmanje 3 varijacije aminokiselina u odnosu na peptid iz kojeg je dobiven i koji je sposoban generirati jednak ili veći odgovor T stanica kod subjekta osjetljivog na gluten kao peptid iz kojeg je dobiven.
4. Pripravak prema zahtjevu 3, naznačen time da dodatno sadrži jedan ili više polinukleotida koji kodiraju jedan ili više dodatnih peptida koji sadrže sekvencu aminokiseline odabranu iz skupine koja sadrži SEQ ID BR: 47, 48, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 75, 76, 77, 78, 79, 80, 81, 89, 90, 91, 92, 95, 102, 103, 104, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 136, 169, 170, 171, 172, 173, 174, 177, 178, 179, 180, 183, 184, 187, 188, 189, 190, 191, 192, 209, i 210.
5. Pripravak naznačen time da sadrži
i) prvi peptid kao što je definirano u zahtjevu 1 ili polinukleotid koji kodira prvi peptid kao što je definirano u zahtjevu 1,
ii) drugi peptid kao što je definirano u zahtjevu 1 ili polinukleotid koji kodira drugi peptid kao što je definirano u zahtjevu 1, i
iii) treći peptid kao što je definirano u zahtjevu 1 ili polinukleotid koji kodira treći peptid kao što je definirano u zahtjevu 1.
6. Cjepivo naznačeno time da sadrži pripravak prema bilo kojem od zahtjeva 1 do 5, i farmaceutski prihvatljiv nosač.
7. Cjepivo prema zahtjevu 6, naznačeno time da dodatno sadrži pomoćno sredstvo.
8. Izolirana stanica za predočavanje antigena, naznačena time da sadrži peptide, polinukleotid ili polinukleotide prema bilo kojem od patentnih zahtjeva 1 do 5.
9. Izolirana stanica za predočavanje antigena prema zahtjevu 8, naznačena time da stanica za predočavanje antigena je dendritička stanica, makrofag, B-limfocit ili sinusna endotelna stanica jetre.
10. Pripravak prema bilo kojem od zahtjeva 1 do 5, cjepivo prema zahtjevu 6 ili 7, i/ili antigen koji iskazuje stanicu prema zahtjevu 8 ili 9, naznačen time da je za uporabu u:
(a) postupku moduliranja odgovora T stanice na peptid glutena kod subjekta koji je osjetljiv na gluten;
(b) postupku izazivanja imunološke tolerancije na peptid glutena kod subjekta koji je osjetljiv na gluten;
(c) postupku liječenja celijakije kod subjekta koji je osjetljiv na gluten; ili
(d) postupku modificiranja izlučivanja citokina kod subjekta koji je osjetljiv na gluten.
11. Pripravak, cjepivo i/ili stanica koja ispoljava antigen prema zahtjevu 10, za uporabu u postupku kao što je definirano u zahtjevu 10, naznačen time da je u postupku smanjeno izlučivanje interleukina-2 (IL-2), interferona gama (IFNγ) i/ili čimbenika tumorske nekroze alfa (TNFα) i/ili je povećano izlučivanje interleukina-10 (IL-10).
12. Postupak za dijagnosticiranje celijakije kod subjekta, praćenje napredovanja celijakije, ili određivanje djelotvornosti postupka kao što je definirano u zahtjevu 10 ili 11, postupak koji sadrži kontaktiranje uzorka od subjekta s pripravkom prema bilo kojem od zahtjeva 1 do 4, i/ili cjepivom prema zahtjevu 6 ili 7, te određivanje in vitro da li jedan ili više peptida vežu T stanice u uzorku, pri čemu vezanje jednog ili više peptida na T stanice ukazuje da subjekt ima celijakiju, ili je podložan celijakiji.
13. Komplet za provođenje postupka prema zahtjevu 12, naznačen time da komplet sadrži pripravak prema bilo kojem od zahtjeva 1 do 5, i/ili cjepivo prema zahtjevu 6 ili 7, te sredstva za otkrivanje vezanja jednog ili više peptida na T stanice.
14. Postupak za proizvodnju antigena koji iskazuje stanicu prema zahtjevu 8 ili 9, naznačen time da postupak sadrži
i) dobivanje stanice koja ispoljava antigen, te
ii) kontaktiranje stanice in vitro sa pripravkom prema bilo kojem od zahtjeva 1 do 5 i/ili cjepivom prema zahtjevu 6 ili 7.
15. Pripravak prema bilo kojem od zahtjeva 1 do 5, cjepivo prema zahtjevu 6 ili 7, i/ili antigen koji iskazuje stanicu prema zahtjevu 8 ili 9 naznačeni time da su za uporabu za dijagnozu ili liječenje.
16. Postupak za pripremanje cjepiva prema zahtjevu 6 ili 7, naznačen time da postupak sadrži kombiniranje prvog, drugog i trećeg peptida, biološki aktivnih fragmenata, ili biološki aktivnih fragmenata varijanti, s farmaceutski prihvatljivim nosačem.
17. Postupak prema zahtjevu 16, naznačen time da postupak dodatno sadrži kombiniranje jednog ili više dodatnih peptida koji sadrže sekvencu aminokiseline odabranu iz skupine koja sadrži SEQ ID BR: 47, 48, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 75, 76, 77, 78, 79, 80, 81, 89, 90, 91, 92, 95, 102, 103, 104, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 136, 169, 170, 171, 172, 173, 174, 177, 178, 179, 180, 183, 184, 187, 188, 189, 190, 191, 192, 209, i 210.
18. Postupak prema zahtjevu 16 ili 17, naznačen time da postupak dodatno sadrži kombiniranje pomoćnog sredstva.
19. Postupak utvrđivanja da li je drugi pripravak ili hrana u stanju izazvati celijakiju, naznačen time da postupak obuhvaća detektiranje prisutnosti pripravka prema bilo kojem od zahtjeva 1 do 5, u drugom pripravku ili hrani.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11864308P | 2008-11-30 | 2008-11-30 | |
| PCT/AU2009/001556 WO2010060155A1 (en) | 2008-11-30 | 2009-11-30 | Compositions and methods for treatment of celiac disease |
| EP20090828453 EP2367561B1 (en) | 2008-11-30 | 2009-11-30 | Compositions and methods for treatment of celiac disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20150873T1 true HRP20150873T1 (hr) | 2015-11-06 |
Family
ID=42225141
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20150873TT HRP20150873T1 (hr) | 2008-11-30 | 2015-08-18 | Pripravci i postupci za lijeäśenje celijakije |
Country Status (16)
| Country | Link |
|---|---|
| US (5) | US8835603B2 (hr) |
| EP (3) | EP2977053B1 (hr) |
| JP (2) | JP5851243B2 (hr) |
| CN (2) | CN102438643B (hr) |
| AU (1) | AU2009321481B2 (hr) |
| BR (1) | BRPI0922122A2 (hr) |
| CA (2) | CA3042826A1 (hr) |
| DK (2) | DK2367561T3 (hr) |
| ES (2) | ES2642096T3 (hr) |
| HK (3) | HK1162918A1 (hr) |
| HR (1) | HRP20150873T1 (hr) |
| HU (1) | HUE027237T2 (hr) |
| MX (1) | MX346450B (hr) |
| NZ (1) | NZ593474A (hr) |
| PT (1) | PT2367561E (hr) |
| WO (1) | WO2010060155A1 (hr) |
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0212885D0 (en) * | 2002-06-05 | 2002-07-17 | Isis Innovation | Therapeutic epitopes and uses thereof |
| US10105437B2 (en) * | 2004-04-28 | 2018-10-23 | Btg International Limited | Epitopes related to coeliac disease |
| EP2412380B1 (en) | 2004-04-28 | 2021-01-06 | BTG International Limited | Epitopes related to coeliac disease |
| CA3042826A1 (en) | 2008-11-30 | 2010-06-03 | Immusant, Inc. | Compositions and methods for treatment of celiac disease |
| US9517257B2 (en) | 2010-08-10 | 2016-12-13 | Ecole Polytechnique Federale De Lausanne (Epfl) | Erythrocyte-binding therapeutics |
| US9850296B2 (en) | 2010-08-10 | 2017-12-26 | Ecole Polytechnique Federale De Lausanne (Epfl) | Erythrocyte-binding therapeutics |
| US9518087B2 (en) | 2010-08-10 | 2016-12-13 | Ecole Polytechnique Federale De Lausanne (Epfl) | Erythrocyte-binding therapeutics |
| RU2017137415A (ru) * | 2011-01-20 | 2019-02-11 | Иммьюносайнсиз Лаб, Инк. | Способы и устройство для обнаружения глютеновой чувствительности и ее дифференцирования с целиакией |
| ITRM20110487A1 (it) * | 2011-09-19 | 2013-03-20 | Consiglio Per La Ricerca E La Speri Mentazione In | Peptidi aventi effetto protettivo nei confronti della attività infiammatoria del peptide 31-43 della a-gliadina nella malattia celiaca. |
| ES2402286B1 (es) * | 2011-09-29 | 2014-03-04 | Universidad De Valladolid | Péptido inmunogénico del gluten y sus aplicaciones. |
| JP6012767B2 (ja) | 2012-02-07 | 2016-10-25 | ヴィブラント ホールディングス リミテッド ライアビリティ カンパニー | 基板、ペプチドアレイ、および方法 |
| PL2863942T3 (pl) | 2012-06-21 | 2019-12-31 | Northwestern University | Cząstki sprzężone z peptydem |
| US10006909B2 (en) | 2012-09-28 | 2018-06-26 | Vibrant Holdings, Llc | Methods, systems, and arrays for biomolecular analysis |
| US10286376B2 (en) | 2012-11-14 | 2019-05-14 | Vibrant Holdings, Llc | Substrates, systems, and methods for array synthesis and biomolecular analysis |
| EP2928500B1 (en) | 2012-12-04 | 2019-03-06 | Phosphorex Inc. | Microparticles and nanoparticles having negative surface charges |
| JP6725413B2 (ja) | 2013-03-13 | 2020-07-15 | クール ファーマシューティカルズ ディベロップメント カンパニー インコーポレイテッド | 炎症の治療のための免疫修飾粒子 |
| EP2970893A4 (en) * | 2013-03-14 | 2016-12-14 | Immusant Inc | PLACEBO CONTROLLED GLUTEN PROVOCATION METHOD |
| AU2014262682A1 (en) * | 2013-05-08 | 2015-12-17 | Rutgers, The State University Of New Jersey | Compositions and methods for the production of gluten free food products |
| BR112016003084A2 (pt) | 2013-08-13 | 2017-09-12 | Univ Northwestern | partículas conjugadas com peptídeo |
| AU2014318889B2 (en) * | 2013-09-10 | 2020-02-20 | Immusant, Inc. | Dosage of a gluten peptide composition |
| CA2925000A1 (en) * | 2013-09-20 | 2015-03-26 | Immusant, Inc. | Compositions and methods related to oat sensitivity |
| US10046056B2 (en) | 2014-02-21 | 2018-08-14 | École Polytechnique Fédérale De Lausanne (Epfl) | Glycotargeting therapeutics |
| ES2874884T3 (es) | 2014-02-21 | 2021-11-05 | Ecole Polytechnique Fed De Lausanne Epfl Epfl Tto | Compuestos terapéuticos dirigidos a la glucosa |
| US10946079B2 (en) | 2014-02-21 | 2021-03-16 | Ecole Polytechnique Federale De Lausanne | Glycotargeting therapeutics |
| US10953101B2 (en) | 2014-02-21 | 2021-03-23 | École Polytechnique Fédérale De Lausanne (Epfl) | Glycotargeting therapeutics |
| WO2015164747A1 (en) * | 2014-04-24 | 2015-10-29 | Immusant, Inc. | Methods for diagnosing celiac disease using circulating cytokines/chemokines |
| JP6887945B2 (ja) * | 2014-09-10 | 2021-06-16 | ヴィブラント ホールディングス リミテッド ライアビリティ カンパニー | セリアック病に関するペプチドマイクロアレイおよび新規バイオマーカー |
| EP3201354A1 (en) | 2014-09-29 | 2017-08-09 | Immusant Inc. | Use of hla genetic status to assess or select treatment of celiac disease |
| CA2968422A1 (en) | 2014-11-21 | 2016-05-26 | Immusant, Inc. | Peptides for use in treatment and diagnosis of type 1 diabetes |
| KR101736744B1 (ko) | 2014-12-03 | 2017-05-17 | 주식회사 한국유전자정보연구원 | 셀리악병 진단용 프라이머 세트와 이를 이용한 셀리악병 진단방법 |
| US10676723B2 (en) | 2015-05-11 | 2020-06-09 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
| US20180250359A1 (en) * | 2015-08-30 | 2018-09-06 | Diamyd Medical Ab | Combination therapy using gliadin and gamma aminobutyric acid |
| JP7194593B2 (ja) | 2015-12-23 | 2022-12-22 | クール ファーマシューティカルズ ディベロップメント カンパニー インコーポレイテッド | 共有ポリマー抗原コンジュゲート化粒子 |
| WO2017143346A1 (en) | 2016-02-18 | 2017-08-24 | Cour Pharmaceuticals Development Company, Inc. | Process for the preparation of tolerizing immune-modulating particles |
| WO2017212476A1 (en) * | 2016-06-05 | 2017-12-14 | Tel Hashomer Medical Research Infrastructure And Services Ltd. | Novel molecules for the treatment of inflammation |
| AU2017290080A1 (en) | 2016-06-28 | 2019-01-24 | Immusant, Inc. | Escalating dosage schedules for treating celiac disease |
| RU2763311C2 (ru) * | 2017-01-12 | 2021-12-28 | Проби Аб | Пробиотические композиции и их применение |
| US10538808B2 (en) | 2017-05-26 | 2020-01-21 | Vibrant Holdings, Llc | Photoactive compounds and methods for biomolecule detection and sequencing |
| WO2018232176A1 (en) | 2017-06-16 | 2018-12-20 | The University Of Chicago | Compositions and methods for inducing immune tolerance |
| CA3080716A1 (en) * | 2017-10-30 | 2019-05-09 | Immusant, Inc. | Dosing regimens for celiac disease |
| JP6568193B2 (ja) | 2017-12-19 | 2019-08-28 | ホーユー株式会社 | エピトープ |
| CN111867565A (zh) * | 2018-02-08 | 2020-10-30 | 库尔制药发展公司股份有限公司 | 使用耐受颗粒治疗乳糜泻 |
| JPWO2020090979A1 (ja) * | 2018-10-31 | 2021-09-24 | 味の素株式会社 | 抗体に対する親和性物質、切断性部分および反応性基を有する化合物またはその塩 |
| WO2020181272A1 (en) * | 2019-03-06 | 2020-09-10 | Cue Biopharma, Inc. | Antigen-presenting polypeptides with chemical conjugation sites and methods of use thereof |
| JP7374687B2 (ja) * | 2019-09-26 | 2023-11-07 | 三和酒類株式会社 | ペンタペプチド化合物 |
| WO2021102182A1 (en) * | 2019-11-19 | 2021-05-27 | Spark Therapeutics, Inc. | Secretable protein induced immune tolerization and treatment of autoimmune, allergic and other diseases and disorders |
| CA3215545A1 (en) | 2021-04-16 | 2022-10-20 | John PUISIS | Method of tracking maintenance of immunological tolerance |
| WO2024020127A1 (en) | 2022-07-21 | 2024-01-25 | Antiva Biosciences, Inc. | Compositions and dosage forms for treatment of hpv infection and hpv-induced neoplasia |
Family Cites Families (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4740371A (en) | 1984-09-17 | 1988-04-26 | International Institute Of Cellular And Molecular Pathology | Treatment of allergy |
| WO1987005400A1 (en) | 1986-03-06 | 1987-09-11 | Commonwealth Scientific And Industrial Research Or | In vitro assay for detecting cell-mediated immune responses |
| FR2615622B1 (fr) | 1987-05-19 | 1994-05-06 | Ire Medgenix Sa | Dosage plasmatique de monokines |
| US5547669A (en) | 1989-11-03 | 1996-08-20 | Immulogic Pharma Corp | Recombinant peptides comprising T cell epitopes of the cat allergen, Fel d I |
| US5998366A (en) | 1990-09-21 | 1999-12-07 | The Regents Of The University Of California | Method for ameliorating glutamic acid decarboxylase associated autoimmune disorders |
| US5674978A (en) | 1990-09-21 | 1997-10-07 | The Regents Of The University Of California | Peptides derived from glutamic acid decarboxylase |
| IL105153A (en) | 1992-03-25 | 1999-12-22 | Immulogic Pharma Corp | Therapeutic compositions comprising peptides derived from human t cell reactive feline protein |
| US5587308A (en) | 1992-06-02 | 1996-12-24 | The United States Of America As Represented By The Department Of Health & Human Services | Modified adeno-associated virus vector capable of expression from a novel promoter |
| WO1996006630A1 (en) | 1994-08-26 | 1996-03-07 | The Regents Of The University Of California | Methods and compositions for modulating a t cell response |
| US6759234B1 (en) | 1994-09-02 | 2004-07-06 | Immulogic Pharmaceutical Corporation | Compositions and methods for administering to humans, peptides capable of down regulating an antigen specific immune response |
| JPH10505356A (ja) | 1994-09-02 | 1998-05-26 | イミユロジク・フアーマシユーチカル・コーポレーシヨン | ヒトへの投与のための組成物および方法、抗原特異的免疫応答のダウンレギュレーションを行うことが可能なペプチド |
| US5750356A (en) | 1996-05-31 | 1998-05-12 | Anergen, Inc. | Method for monitoring T cell reactivity |
| EP0905518A1 (en) | 1997-09-23 | 1999-03-31 | Academisch Ziekenhuis Leiden | Peptides specific for gluten-sensitive T-cells and use thereof |
| US6300308B1 (en) | 1997-12-31 | 2001-10-09 | Board Of Regents, The University Of Texas System | Methods and compositions for inducing autoimmunity in the treatment of cancers |
| GB9923306D0 (en) | 1999-10-01 | 1999-12-08 | Isis Innovation | Diagnostic and therapeutic epitope, and transgenic plant |
| US6667160B2 (en) | 2000-03-15 | 2003-12-23 | Kenneth D. Fine | Method for diagnosing immunologic food sensitivity |
| US8110218B2 (en) | 2000-11-30 | 2012-02-07 | The Research Foundation Of State University Of New York | Compositions and methods for less immunogenic protein-lipid complexes |
| EP1241476A1 (en) | 2001-03-12 | 2002-09-18 | Mabtech AB | Diagnosis of metal allergy through cytokine release by T-cells in vitro |
| CA2440474A1 (en) | 2001-04-05 | 2002-10-17 | Virginia Mason Research Center | Methods of mhc class ii epitope mapping, detection of autoimmune t cells and antigens, and autoimmune treatment |
| EP1377604B1 (en) | 2001-04-12 | 2014-12-31 | Academisch Ziekenhuis Leiden | Methods and means for use of hla-dq restricted t-cell receptors and hla-dq-binding prolamine-derived peptides |
| FI20010868A0 (fi) | 2001-04-25 | 2001-04-25 | Markku Maeki | Menetelmä ja välineet gluteenin indusoimien tautien havaitsemiseksi |
| AU2002347369A1 (en) | 2001-12-05 | 2003-06-17 | Circassia Limited | Immunotherapeutic methods and systems |
| EP1332760A1 (en) | 2002-02-04 | 2003-08-06 | Academisch Ziekenhuis Leiden | Novel epitopes for celiac disease and autoimmune diseases, methods for detecting those and novel non-antigenic food compounds |
| US7320788B2 (en) | 2002-02-14 | 2008-01-22 | The Board Of Trustees Of The Leland Stanford Junior University | Enzyme treatment of foodstuffs for Celiac Sprue |
| ATE505201T1 (de) | 2002-02-14 | 2011-04-15 | Univ Leland Stanford Junior | Enzymbehandlung von nahrungsmitteln für zöliakie- sprue |
| US7462688B2 (en) | 2002-05-14 | 2008-12-09 | The Board Of Trustees Of The Leland Stanford Junior University | Peptides for diagnostic and therapeutic methods for celiac sprue |
| US7202216B2 (en) | 2002-05-14 | 2007-04-10 | The Board Of Trustees Of The Leland Stanford Junior University | Drug therapy for celiac sprue |
| CA2487247A1 (en) | 2002-05-14 | 2003-11-27 | The Board Of Trustees Of The Leland Stanford Junior University | Drug therapy for celiac sprue |
| GB0212885D0 (en) | 2002-06-05 | 2002-07-17 | Isis Innovation | Therapeutic epitopes and uses thereof |
| AU2002952834A0 (en) * | 2002-09-16 | 2002-12-05 | The Walter And Eliza Hall Institute Of Medical Research | A method of treating an autoimmune disease |
| AU2002952548A0 (en) | 2002-11-08 | 2002-11-21 | Cellestis Limited | Diagnostic assay |
| AU2003277989B2 (en) | 2002-11-08 | 2010-04-22 | QIAGEN Australia Holding Pty. Ltd. | Diagnostic assay for measuring a cell mediated immune response |
| EP1563300B1 (en) | 2002-11-20 | 2012-04-18 | The Board Of Trustees Of The Leland Stanford Junior University | Diagnostic method for celiac sprue |
| US7563864B2 (en) * | 2004-04-26 | 2009-07-21 | Celiac Sprue Research Foundation | Prolyl endopeptidase mediated destruction of T cell epitopes in whole gluten |
| EP2412380B1 (en) * | 2004-04-28 | 2021-01-06 | BTG International Limited | Epitopes related to coeliac disease |
| GB0409775D0 (en) | 2004-04-30 | 2004-06-09 | Mabtech Ab | Assay |
| AU2005302425A1 (en) | 2004-10-29 | 2006-05-11 | Benaroya Research Institute At Virginia Mason | Methods of generating antigen-specific CD4+CD25+ regulatory T cells, compositions and methods of use |
| EP1937300A4 (en) | 2005-08-17 | 2009-08-12 | Multicell Immunotherapeutics I | METHOD AND COMPOSITIONS FOR CREATING AND CONTROLLING THE EFFECTOR PROFILE OF T-CELLS BY SIMULTANEOUS LOADING AND ACTIVATION OF SELECTED SUB-GROUPS OF ANTIGEN-PRESENTING CELLS |
| US20090304754A1 (en) | 2005-10-12 | 2009-12-10 | Srebrenka Robic | Pegylated glutenase polypeptides |
| JP2009536157A (ja) | 2006-04-13 | 2009-10-08 | ペプチミューン，インコーポレイテッド | エピトープ透過性の指向された拡張を介した指向性配列ポリマー組成物の設計方法および合成方法 |
| CA3037889C (en) * | 2007-01-25 | 2022-09-13 | Intrexon Actobiotics Nv | Treatment of immune disease by mucosal delivery of antigens |
| ITFE20070003A1 (it) | 2007-02-01 | 2007-05-03 | Girolamo Calo' | Utilizzo di peptidi ricchi in prolina e glutamina capaci di legarsi alle molecole hla-dq2 e dq8 come "carriers specifici" di agenti capaci di danneggiare o uccidere le cellule che esprimono dette molecole hla nel contesto dell a mucosa enterica di pa |
| ES2558543T3 (es) | 2007-03-16 | 2016-02-05 | Cellestis Limited | Un ensayo de respuesta inmunitaria mediada por células y kits para el mismo |
| CA2721582C (en) | 2008-04-21 | 2017-07-11 | Bio-Rad Laboratories, Inc. | Recombinant deamidated gliadin antigen |
| EP2277046A2 (en) | 2008-05-16 | 2011-01-26 | The Board of Trustees of The Leland Stanford Junior University | Non-inflammatory gluten peptide analogues as biomarkers for celiac sprue |
| AU2009273749B2 (en) | 2008-07-25 | 2016-04-21 | QIAGEN Australia Holding Pty. Ltd. | A diagnostic method |
| CA3042826A1 (en) | 2008-11-30 | 2010-06-03 | Immusant, Inc. | Compositions and methods for treatment of celiac disease |
| US20120107847A1 (en) | 2009-07-02 | 2012-05-03 | Dsm Ip Assets B.V. | Testing efficacy for celiac disease |
| AU2010336016B2 (en) | 2009-12-23 | 2017-07-27 | QIAGEN Australia Holding Pty. Ltd. | An assay for measuring cell-mediated immunoresponsiveness |
| WO2011146968A1 (en) | 2010-05-28 | 2011-12-01 | Cellestis Limited | A diagnostic assay |
| US20110311536A1 (en) | 2010-06-11 | 2011-12-22 | Dana-Farber Cancer Institute, Inc. | Prevention of type 1 diabetes by treg vaccination with an insulin mimetope |
| ES2673697T5 (es) | 2011-06-29 | 2022-09-14 | Cellestis Ltd | Un ensayo de la respuesta inmunitaria mediada por células con sensibilidad incrementada |
| WO2013016427A1 (en) | 2011-07-25 | 2013-01-31 | Alvine Pharmaceuticals, Inc. | Methods and pharmaceutical compositions for treating celiac disease and gluten intolerance |
| WO2013036294A1 (en) | 2011-09-06 | 2013-03-14 | Selecta Biosciences, Inc. | Antigen-specific induced tolerogenic dendritic cells to reduce cytotoxic t lymphocyte responses |
| ES2402286B1 (es) | 2011-09-29 | 2014-03-04 | Universidad De Valladolid | Péptido inmunogénico del gluten y sus aplicaciones. |
| JP6148250B2 (ja) | 2011-12-05 | 2017-06-14 | バイオ−ラッド ラボラトリーズ，インコーポレイティド | 組換え脱アミド化グリアジン抗原 |
| EP2970893A4 (en) | 2013-03-14 | 2016-12-14 | Immusant Inc | PLACEBO CONTROLLED GLUTEN PROVOCATION METHOD |
| AU2014318889B2 (en) | 2013-09-10 | 2020-02-20 | Immusant, Inc. | Dosage of a gluten peptide composition |
| CA2925000A1 (en) | 2013-09-20 | 2015-03-26 | Immusant, Inc. | Compositions and methods related to oat sensitivity |
| WO2015164747A1 (en) | 2014-04-24 | 2015-10-29 | Immusant, Inc. | Methods for diagnosing celiac disease using circulating cytokines/chemokines |
-
2009
- 2009-11-30 CA CA3042826A patent/CA3042826A1/en not_active Abandoned
- 2009-11-30 EP EP15168279.6A patent/EP2977053B1/en not_active Not-in-force
- 2009-11-30 ES ES15168279.6T patent/ES2642096T3/es active Active
- 2009-11-30 JP JP2011537796A patent/JP5851243B2/ja not_active Expired - Fee Related
- 2009-11-30 EP EP17175226.4A patent/EP3269379A1/en not_active Withdrawn
- 2009-11-30 PT PT98284532T patent/PT2367561E/pt unknown
- 2009-11-30 EP EP20090828453 patent/EP2367561B1/en active Active
- 2009-11-30 WO PCT/AU2009/001556 patent/WO2010060155A1/en active Application Filing
- 2009-11-30 DK DK09828453.2T patent/DK2367561T3/en active
- 2009-11-30 HU HUE09828453A patent/HUE027237T2/en unknown
- 2009-11-30 BR BRPI0922122A patent/BRPI0922122A2/pt not_active IP Right Cessation
- 2009-11-30 AU AU2009321481A patent/AU2009321481B2/en not_active Ceased
- 2009-11-30 MX MX2011005632A patent/MX346450B/es active IP Right Grant
- 2009-11-30 CA CA2744787A patent/CA2744787C/en active Active
- 2009-11-30 ES ES09828453.2T patent/ES2549481T3/es active Active
- 2009-11-30 US US13/131,787 patent/US8835603B2/en active Active
- 2009-11-30 DK DK15168279.6T patent/DK2977053T3/en active
- 2009-11-30 CN CN200980155615.9A patent/CN102438643B/zh not_active Expired - Fee Related
- 2009-11-30 NZ NZ593474A patent/NZ593474A/xx not_active IP Right Cessation
- 2009-11-30 CN CN201510292861.6A patent/CN105079781B/zh not_active Expired - Fee Related
-
2012
- 2012-03-28 HK HK12103049.1A patent/HK1162918A1/xx not_active IP Right Cessation
-
2014
- 2014-08-13 US US14/459,060 patent/US9464120B2/en active Active
-
2015
- 2015-08-18 HR HRP20150873TT patent/HRP20150873T1/hr unknown
- 2015-12-01 JP JP2015235197A patent/JP6027215B2/ja not_active Expired - Fee Related
-
2016
- 2016-07-11 HK HK16108040.5A patent/HK1219898A1/zh not_active IP Right Cessation
- 2016-09-09 US US15/260,990 patent/US20170158743A1/en not_active Abandoned
-
2018
- 2018-06-18 US US16/010,596 patent/US20190048047A1/en not_active Abandoned
- 2018-07-16 HK HK18109154.3A patent/HK1249446A1/zh unknown
-
2020
- 2020-05-27 US US16/884,533 patent/US20210115096A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20150873T1 (hr) | Pripravci i postupci za lijeäśenje celijakije | |
| JP2012510431A5 (hr) | ||
| ES2528766T3 (es) | Péptido auxiliar antigénico de cáncer | |
| JP2008530975A5 (hr) | ||
| HRP20100354T1 (hr) | Nova formulacija tumoru pridruženih peptida koji se vežu na antigene humanih leukocita (hla) razreda i i ii za uporabu u cjepivima | |
| JP2010531139A5 (hr) | ||
| RU2020113032A (ru) | Новые пептиды и комбинации пептидов для применения в иммунотерапии рака легких, в том числе немелкоклеточного рака легких (нмрл) и других видов рака | |
| HRP20141233T1 (hr) | PEPTIDNA CJEPIVA DOBIVENA IZ EphA4 | |
| JP2018510622A5 (hr) | ||
| RU2012153218A (ru) | Пептиды, проникающие в клетки, и их применения | |
| JP2013517783A5 (hr) | ||
| JP2013513377A5 (hr) | ||
| RU2013128896A (ru) | Сконструированные белки повторов, которые связываются с сывороточным альбумином | |
| HRP20110368T1 (hr) | Biološki aktivni proteini s povećanom stabilnošću in vivo i/ili in vitro | |
| JP2009506762A5 (hr) | ||
| NZ562436A (en) | Toll-like receptor 14 (TLR14) and use thereof | |
| JP2014509838A5 (hr) | ||
| BRPI0411363A (pt) | seqüências de ácidos nucléicos codificando e composições compreendendo peptìdeo sinal ige e/ou il-15 e processos para uso das mesmas | |
| RU2015103816A (ru) | ПРОНИКАЮЩИЕ В КЛЕТКУ ПЕПТИДЫ, МИШЕНЬЮ КОТОРЫХ ЯВЛЯЕТСЯ eIF4E | |
| JP2010533735A5 (hr) | ||
| JP2013523084A5 (hr) | ||
| RU2012147590A (ru) | Пептиды cdca5 и содержащие их вакцины | |
| RU2014121502A (ru) | Пептиды торк и содержащие их вакцины | |
| RU2012136464A (ru) | Модифицированные пептиды melk и содержащие их вакцины | |
| JP2010535504A5 (hr) |